The company said the FDA approved Icotyde to treat moderate to severe plaque psoriasis in adults and pediatric patients 12 ...
Pharmaceutical Technology on MSN
J&J wins FDA approval for Icotyde to enter psoriasis pill market
J&J’s Icotyde will take on AbbVie’s blockbuster injectable Skyrizi as analysts forecast a blockbuster future for the pill.
Johnson & Johnson and Protagonist Therapeutics are countering the swarm of injectable biologics that have long dominated the ...
Icotyde is the first targeted oral peptide IL‑23 receptor antagonist, designed to interrupt a core psoriasis inflammatory axis while avoiding injection-based administration typical of IL‑23 biologics.
Johnson & Johnson won U.S. approval for a daily psoriasis pill that rivals the benefits of injectable medicines and could ...
A >500-patient, randomized, double-blind phase 3 trial showed CT-P43 achieved PASI 75 equivalence at week 12 versus ...
This is the first IL-23 receptor-targeted oral peptide pill, and it is also being evaluated as a treatment for psoriatic ...
FDA approval covers adults and adolescents ≥12 years (≥88 lbs) with moderate-to-severe plaque psoriasis requiring systemic ...
"Walking around with this very visible, very robust ailment has a pretty tremendous impact on your mental health," Maddox ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results